Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 9/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 9/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FABP2 | P12104 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23070482 | 0.84 | AKR1C3 (0.69) | AKR1C3AKR1C2PTGS1PTGS2MEN1 | |
| SCHEMBL12263193 | 0.83 | CYP2C19 (0.44) | AKR1C3AKR1C2PTGS1PTGS2MEN1 | |
| SCHEMBL12263206 | 0.82 | PGR (0.43) | AKR1C3AKR1C2PTGS1PTGS2MEN1 | |
| SCHEMBL12326412 | 0.80 | GABRG2 (0.48) | AKR1C3AKR1C2GABRG2GABRB3GABRA5 | |
| SCHEMBL24017180 | 0.80 | GABRG2 (0.64) | GABRG2GABRB3GABRA5GABRA3ADRA2C | |
| SCHEMBL12570867 | 0.80 | AKR1C3 (0.51) | AKR1C3AKR1C2PTGS1PTGS2MEN1 | |
| SCHEMBL8240673 | 0.79 | CLK4 (0.49) | GABRG2GABRB3GABRA5GABRA3PSEN1 | |
| SCHEMBL19579266 | 0.79 | ADRA2C (0.54) | GABRG2GABRB3GABRA5GABRA3ADRA2C | |
| SCHEMBL12919972 | 0.78 | ADAMTS4 (0.48) | GABRG2GABRB3GABRA5GABRA3CYP1A2 | |
| SCHEMBL12263195 | 0.78 | CYP11B1 (0.49) | AKR1C3AKR1C2PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200397774-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORPORATION | 2020-12-24 | — | — | US | disclosed |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-9999619-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170246157-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2017-08-31 | — | — | US | disclosed |
| US-20170246157-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2017-08-31 | — | — | US | disclosed |
| US-9464088-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140275031-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-8765734-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE CORPORATION (US) | 2014-07-01 | — | — | US | disclosed |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397774-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | AKR1C3 4087/4885AKR1C2 3588/4885GABRG2 907/4885 |
| US-20140275031-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | AKR1C3 4087/4885AKR1C2 3588/4885GABRG2 907/4885 |
| US-20170246157-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | AKR1C3 4087/4885AKR1C2 3588/4885GABRG2 907/4885 |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | AKR1C3 4087/4885AKR1C2 3588/4885GABRG2 907/4885 |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | JAK1, JAK2, JAK3 | AKR1C3 4087/4885AKR1C2 3588/4885GABRG2 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.